DexCom (NASDAQ:DXCM) Lowered to “Hold” at StockNews.com

DexCom (NASDAQ:DXCM) was downgraded by stock analysts at StockNews.com from a “buy” rating to a “hold” rating in a report released on Saturday.

DXCM has been the topic of several other research reports. Royal Bank of Canada started coverage on shares of DexCom in a report on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price target on the stock. Canaccord Genuity Group boosted their target price on DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a research report on Friday, April 26th. Raymond James lifted their price target on shares of DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a research note on Friday, April 26th. UBS Group upped their price target on shares of DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a research report on Wednesday, April 10th. Finally, Citigroup lifted their price objective on shares of DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Three research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, DexCom currently has a consensus rating of “Moderate Buy” and an average price target of $141.67.

DexCom Stock Up 1.4 %

Shares of DexCom stock opened at $127.37 on Friday. The company has a debt-to-equity ratio of 1.08, a current ratio of 2.90 and a quick ratio of 2.53. The company has a 50-day moving average of $132.96 and a 200 day moving average of $124.23. DexCom has a 1 year low of $74.75 and a 1 year high of $142.00. The firm has a market cap of $50.65 billion, a price-to-earnings ratio of 82.17, a PEG ratio of 3.19 and a beta of 1.23.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.05. The firm had revenue of $921.00 million during the quarter, compared to analysts’ expectations of $911.20 million. DexCom had a return on equity of 31.01% and a net margin of 16.82%. As a group, sell-side analysts anticipate that DexCom will post 1.78 earnings per share for the current fiscal year.

Insider Activity at DexCom

In other news, EVP Sadie Stern sold 20,321 shares of DexCom stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $133.61, for a total value of $2,715,088.81. Following the completion of the transaction, the executive vice president now owns 80,441 shares in the company, valued at approximately $10,747,722.01. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other DexCom news, EVP Michael Jon Brown sold 2,624 shares of the company’s stock in a transaction on Thursday, March 28th. The stock was sold at an average price of $140.04, for a total value of $367,464.96. Following the transaction, the executive vice president now owns 68,682 shares of the company’s stock, valued at $9,618,227.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Sadie Stern sold 20,321 shares of DexCom stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $133.61, for a total value of $2,715,088.81. Following the completion of the transaction, the executive vice president now directly owns 80,441 shares in the company, valued at approximately $10,747,722.01. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 186,641 shares of company stock valued at $25,217,707. Insiders own 0.30% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in DXCM. Vanguard Group Inc. grew its holdings in DexCom by 0.3% during the first quarter. Vanguard Group Inc. now owns 44,603,745 shares of the medical device company’s stock valued at $6,186,539,000 after purchasing an additional 136,282 shares during the last quarter. Capital Research Global Investors boosted its stake in shares of DexCom by 21.4% in the 4th quarter. Capital Research Global Investors now owns 15,296,032 shares of the medical device company’s stock valued at $1,898,085,000 after purchasing an additional 2,695,296 shares in the last quarter. Sands Capital Management LLC grew its position in DexCom by 10.2% during the 4th quarter. Sands Capital Management LLC now owns 15,058,806 shares of the medical device company’s stock worth $1,868,647,000 after acquiring an additional 1,398,136 shares during the last quarter. Capital World Investors grew its holdings in DexCom by 130.7% during the 4th quarter. Capital World Investors now owns 9,278,685 shares of the medical device company’s stock worth $1,151,392,000 after acquiring an additional 5,256,092 shares during the last quarter. Finally, Artisan Partners Limited Partnership increased its stake in shares of DexCom by 164.8% in the 4th quarter. Artisan Partners Limited Partnership now owns 5,900,308 shares of the medical device company’s stock valued at $732,169,000 after buying an additional 3,672,471 shares during the period. 97.75% of the stock is owned by hedge funds and other institutional investors.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.